WELL Health: Canaccord Increases Price Target To $8.50 Following Bought Deal

This morning Canaccord Genuity raised their 12-month price target on WELL Health Technologies (TSX: WELL) to C$8.50 from C$8.00 and reiterated their Speculative Buy recommendation on the stock following the close of their recent $80 million bought deal.

Doug Taylor, Canaccord’s analyst, now estimates that the company holds roughly $114 million in pro forma cash. Funds from the recent financing are expected to go towards “organic growth initiatives, including its recent apps.health launch, and for additional M&A and strategic investments.”

Taylor says, “Financing strengthens an already sizable war chest for accretive capital allocation.” He adds that the sizeable $114 million in cash WELL has now will go towards M&A or a list of strategic investments, such as the following.

  1. Medical and/or allied health clinics (WELL Health Clinic Network and WELL Allied)
  2. EMR platforms (WELL EMR)
  3. Digital health companies with an emphasis on patient engagement technologies (WELL Digital Health Apps)
  4. Cybersecurity (Cycura)

Although since the Circle Medical deal that was signed at the beginning of September, there has been no new deals, Taylor says, “we understand
the company currently has on the order of 10 signed letters of intent (LOI) in its M&A pipeline, noting that timing and probability of closing from the LOI stage are variable.”

Taylor then touches on their forecast for WELL’s third-quarter results, which will be announced in November. Taylor says that they expect a small growth in Digital Services revenue over the second quarter. This quarter will include early contributions from the Cycura acquisition.

Taylor expects third-quarter revenue to be $11 million and Adjusted EBITDA to be ($0.4) million. His full 2020 year revenue estimate is $44 million with EBITDA of ($0.8) million.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Eldorado Gold: The $3.8 Billion Foran Mining Acquisition

Silver Tiger’s $2.35B Silver Blueprint: Two Mines, One Perfect Metals Market

Gold Is At Records. Barrick Mining Is Printing Cash. The Stock Still Fell. | Q4 Earnings

Recommended

Canadian Copper Plans 2,500 Metre Drill Program For 2026

Mercado Receives Permits For Planned 3,000 Metre Drill Program At Copalito

Related News

Valens Company: Analysts Downgrade Company Following Reduced Guidance

The Valens Company (TSX: VLNS) experienced a pretty wild second half of January, and analysts...

Monday, February 1, 2021, 02:39:00 PM

Well Health Sees Patient Visits Post Continued Growth In Q3

Well Health (TSX: WELL) this morning released preliminary third quarter results as it looks to...

Wednesday, November 2, 2022, 08:29:47 AM

Small Pharma: Canaccord Initiates Coverage With $1.00 Price Target

Canaccord Genuity recently initiated coverage on Small Pharma Inc (TSXV: DMT), a company that is...

Sunday, June 13, 2021, 01:08:00 PM

Valens: Canaccord Lowers Price Target To $3.75

Earlier this month, The Valens Company (TSX: VLNS) reported their fiscal third-quarter financial results. The...

Sunday, October 31, 2021, 10:10:00 AM

Enthusiast Gaming: Canaccord Raises Price Target To $12

On March 22nd, Enthusiast Gaming (TSX: EGLX) released their fourth-quarter earnings and announced a partnership...

Sunday, March 28, 2021, 02:39:00 PM